HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a response Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ross, R K Articles by Henderson, B E Search for Related Content PubMed PubMed Citation Articles by Ross, R K Articles by Henderson, B E

Past and present preferred prescribing practices of hormone replacement therapy among Los Angeles gynecologists: possible implications for public health.

R K Ross, A Paganini-Hill, S Roy, A Chao and B E Henderson

Department of Preventive Medicine, University of Southern California School of Medicine, Norris Cancer Hospital, Los Angeles 90033-0804.

Usual prescribing strategies of hormone replacement therapy for postmenopausal women by Los Angeles area gynecologists, both now and 10 years ago, were investigated by a mail survey. Of the 330 gynecologists who responded, estrogen therapy is currently used as a routine by nearly all (95 per cent), for women both with and without a uterus. Over three-fourths of these physicians favor use of 0.625 mg of conjugated equine estrogen. The estrogen is combined with cyclic progestin therapy, usually 10 mg of medroxyprogesterone acetate, by 86 per cent of gynecologists using estrogen for women with a uterus, and by 47 per cent for women without a uterus. Although conjugated equine estrogens were used widely for both groups of patients 10 years ago, a higher dose generally was preferred. Use of progestin therapy was uncommon (less than 20 per cent) for any postmenopausal patients at that time. Although the most common monthly therapeutic regimen for estrogen/progestin therapy is estrogen for days 1-25 and progestin for days 16-25, there is wide variation in prescribing strategies. We present these findings in the context of the probable effects of estrogen/progestin therapy on various chronic disease outcomes.

This article has been cited by other articles:

				B. L. Strom, R. Schinnar, A. L. Weber, G. Bunin, J. A. Berlin, M. Baumgarten, A. DeMichele, S. C. Rubin, M. Berlin, A. B. Troxel, et al. Case-Control Study of Postmenopausal Hormone Replacement Therapy and Endometrial Cancer Am. J. Epidemiol., October 15, 2006; 164(8): 775 - 786. [Abstract] [Full Text] [PDF]

				T. R. Rebbeck, A. B. Troxel, Y. Wang, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, G. Bunin, A. DeMichele, et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst, September 20, 2006; 98(18): 1311 - 1320. [Abstract] [Full Text] [PDF]

				R. K. Ross, A. Paganini-Hill, P. C. Wan, and M. C. Pike Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin J Natl Cancer Inst, February 16, 2000; 92(4): 328 - 332. [Abstract] [Full Text] [PDF]

				L. Elinson, M. M. Cohen, and T. Elmslie Hormone replacement therapy: a survey of Ontario physicians' prescribing practices Can. Med. Assoc. J., September 1, 1999; 161(6): 695 - 698. [Abstract] [Full Text] [PDF]

				J. V. R. MARSH, K. M. BRETT, and L. C. MILLER Racial Differences in Hormone Replacement Therapy Prescriptions Obstet. Gynecol., June 1, 1999; 93(6): 999 - 1003. [Abstract] [Full Text] [PDF]

				B. Henderson, R. Ross, and M. Pike Hormonal chemoprevention of cancer in women Science, January 29, 1993; 259(5095): 633 - 638. [Abstract]